Article, News
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…
Media, News
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Article, Media, News
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Article, News
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) to be…
Article, News
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress…
Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, News
Prescient Therapeutics secures speculative buy recommendation from Bioshares
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in…
Article, News
Fight against cancer an enduring investment motivation in September quarter despite markets
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives and compounding economic burdens along the way. The companies dedicated…
Article, News
Prescient Therapeutics to participate in prestigious conference; abstract online now
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society of Hematology (ASH) website ahead of the company’s presentation at…
Article, News
Prescient Therapeutics to present clinical data at prestigious US conference
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted for poster presentation at the prestigious American Society of Hematology…